Spots Global Cancer Trial Database for REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
Official Title: REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
Study ID: NCT05902533
Conditions
Study Description
Brief Summary: To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.
Detailed Description: This is a multi-center, single arm prospective trial to evaluate whether reduced elective nodal dose (30.6 Gy) reduces toxicity as defined by the CTCAE Toxicity Index compared to historic patients treated with standard nodal dose on NRG/RTOG0529 and patient reported GI toxicity using the validated PRO-CTCAE scale for diarrhea compared to historic patients treated on UC-GI-1601.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
University of Vermont, Burlington, Vermont, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
